BCR::ABL1 Tyrosine Kinase Inhibitors During Pregnancy, a Disproportionality Analysis of Vigibase.

ABSTRACT: Tyrosine kinase inhibitors (TKIs) targeting BCR::ABL1 have greatly improved the survival of patients with chronic myeloid leukemia (CML), and their teratogenicity appears as an important factor for individuals of childbearing potential. This study aims to investigate pregnancy and fetal/newborn adverse outcomes resulting from exposure to BCR::ABL1-TKIs during pregnancy. For this disproportionality analysis, we used the WHO's global VigiBase up to January 2024, and included reports involving pregnancy, antineoplastic treatment during pregnancy, and cancer. The exposure group consisted of reports mentioning BCR::ABL1-TKIs at any time during pregnancy. The primary outcome was the reporting odds ratio (ROR) of maternal-fetal complications in the BCR::ABL1-TKIs group compared to other anticance

SUBMITTER: Cabannes-Hamy A 

PROVIDER: S-EPMC12355020 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature